Skip to main content
Premium Trial:

Request an Annual Quote

Antibody Firm AxioMx Closes $2M Financing Round

Premium

Antibody firm AxioMx said this week that it has completed its initial financing round, raising more than $2 million from investors including Connecticut Innovations, Elm Street Ventures, and the company's founders.

Founded this year, AxioMx specializes in the discovery and development of custom recombinant antibodies, offering services including epitope mapping and antigen design as well as antibody screening, affinity maturation, optimization, and production.

The company uses proprietary phage display libraries and a "rapid liquid" screening and affinity maturation technique that it said can bring monoclonal antibody development times down from four to six months to less than four weeks.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.